Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity

Frontiers in Microbiology

Microbiology

Sabine Hazan¹ 

[1] null;

关键词: microbiome;    COVID-19;    SARS-CoV-2;    Bifidobacterium;    TNF-α (tumor necrosis factor a);    ivermectin;   

DOI  :  10.3389/fmicb.2022.952321

 received in 2022-05-25, accepted in 2022-06-10,  发布年份 2022

来源: Frontiers

【 摘 要 】

Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of Streptomyces avermitilis. Bifidobacterium is a member of the same phylum as Streptomyces spp., suggesting it may have a symbiotic relation with Streptomyces. Decreased Bifidobacterium levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of Streptomyces fermentation, is capable of feeding Bifidobacterium, thereby possibly preventing against COVID-19 susceptibilities. Moreover, Bifidobacterium may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.

【 授权许可】

Unknown   
Copyright © 2022 Hazan.